Early Access — free while we kick the tires
EdgarHawk

Dan Benjamin Teleman

Chief Executive Officer

Director Officer

Latest: CEO buying · March 2026

3 filings analyzed · 1 company · Latest 2026-06-22

Companies

Company Buys Sells Direction
Nasus Pharma Ltd NSRX 3 0 Net buying

Activity

June 2026
2026-06-22 Nasus Pharma Ltd NSRX
medium
Buy
6,550 shares
$20,305
Significance 5/10

NSRX CEO Dan Benjamin Teleman buys 6,550 shares at $3.10; holdings now 163,541 shares; stock -69.3% from 52-week high.

CEO Dan Benjamin Teleman purchased 6,550 shares at $3.10 on 2026-06-17, increasing his holdings to 163,541 shares. The purchase occurs while NSRX trades at $3.07, down 69.3% from its 52-week high of $9.99, and represents a +4.2% increase in his pre-transaction holdings. Among his prior NSRX transactions, results have been mixed: his April 2026 buy declined 22.9% over 30 days, while his March 2026 buy gained 32.4% over the same period. His cross-ticker track record shows 2 prior open-market buys averaging +4.7% 30-day returns. The timing context is unclear without structured timing data, but the substantial distance from the 52-week high and modest position addition merit observation.

April 2026
2026-04-22 Nasus Pharma Ltd NSRX
medium
Buy
2,900 shares
$10,904
Significance 5/10

CEO Teleman bought 2,900 shares of NSRX at $3.76 on 2026-04-22, second buy in one month as stock recovered +55.6% in 30 days from 57.5% drawdown.

Teleman Dan Benjamin, Chief Executive Officer, purchased 2,900 shares at $3.76, bringing his total holdings to 156,991 shares (+1.9% from prior level). This marks his second open-market buy at NSRX within 22 days, following a March 31 purchase. The timing coincides with sharp price recovery: the stock is up 55.6% over the past 30 days but remains down 41.3% over 90 days and 57.5% below its 52-week high of $9.15. The CEO's repeated purchasing during this volatile period warrants attention to company fundamentals and any material developments driving the recent rally. At the current $3.89 price, the stock has already appreciated modestly from his transaction price, though its long-term trend remains challenged.

2026-04-01 Nasus Pharma Ltd NSRX
high
Buy
15,000 shares
$30,600
Significance 6/10

CEO Teleman buys 15,000 shares of NSRX at $2.04 amid -72.1% decline from 52-week high

Teleman Dan Benjamin, Chief Executive Officer, purchased 15,000 shares at $2.04 on 2026-03-31, expanding his holdings by 240.2% to 21,246 shares total. The transaction occurs in a context of material stock deterioration: NSRX is trading at $2.55, representing -72.1% from its 52-week high of $9.15 and -44.3% over the last 30 days. The CEO's purchase of a substantial absolute quantity—and tripling of his personal stake—stands out against this backdrop of sharp share price contraction. Without a track record or discretionary-trade FLAGS, the acquisition marks a direct personal capital commitment by the company's top executive at depressed price levels.

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access